Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

946 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM. Mahaffey KW, et al. Among authors: white hd. J Am Coll Cardiol. 1997 Dec;30(7):1606-10. doi: 10.1016/s0735-1097(97)00394-x. J Am Coll Cardiol. 1997. PMID: 9385883 Free article. Clinical Trial.
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee.
Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM. Topol EJ, et al. J Am Coll Cardiol. 1992 May;19(6):1123-8. doi: 10.1016/0735-1097(92)90312-b. J Am Coll Cardiol. 1992. PMID: 1564212 Free article. Clinical Trial.
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-Channing N, Simoons ML, Gore JM, Califf RM, Mark DB. Tung CY, et al. Circulation. 1999 Jan 26;99(3):370-6. doi: 10.1161/01.cir.99.3.370. Circulation. 1999. PMID: 9918523
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, Morris D, Aylward P, Woodlief LH, Topol EJ. Barbash GI, et al. Among authors: white hd. J Am Coll Cardiol. 1995 Nov 1;26(5):1222-9. doi: 10.1016/0735-1097(95)00299-5. J Am Coll Cardiol. 1995. PMID: 7594035 Free article. Clinical Trial.
Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, Modan M, Goldbourt U, White HD, Van de Werf F. Barbash GI, et al. Among authors: white hd. J Am Coll Cardiol. 1993 Feb;21(2):281-6. doi: 10.1016/0735-1097(93)90664-m. J Am Coll Cardiol. 1993. PMID: 8425987 Free article. Clinical Trial.
946 results